USA flag logo/image

An Official Website of the United States Government

Novel antithrombotic agents to prevent hemodialysis vascular access failure

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44HL093848
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
EVAS THERAPEUTICS, LLC.
613 HUNTLEY HEIGHTS DRIVE BALLWIN, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Novel antithrombotic agents to prevent hemodialysis vascular access failure
Agency: HHS
Contract: 2R44HL093848-02
Award Amount: $1,365,616.00
 

Abstract:

DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF creation and 77% at 1 year after AVG construction. Surgical trauma, repeated needle punctures, mechanical shear stress, the foreign graft material and uremia can elicit a strong thrombotic response that lays downa mural fibrin- and platelet-rich substrate on which excessive cell migration, proliferation and matrix deposition occur, leading to neointimal hyperplasia (NH) in the peri-anastomotic regions of AVFs and AVGs. Limiting the early eventof mural thrombosis may thus effectively reduce NH, which is the primary cause of stenosis and subsequent dialysis access failure. Currently available antiplatelet and anticoagulant drugs, however, have inadequate efficacies in preventing NH at clinically safe doses. EVAS Therapeutics has developed two thrombogenic site-targeted fusion Proteins (ANV-6L15 and TAP-ANV), which can specifically dock onto the membrane surfaces of thrombogenic cells and passivate the membrane-associatedenzyme/cofactor complexes that initiate and propagate the clotting cascade. Due to their high-affinity thrombogenic site-targeting properties and relatively short circulating half-lives, the fusion proteins can exert long-lasting antithrombotic effectwithout systemic anticoagulation. This may eliminate the need for long-term antithrombotic therapy and inhibit mural thrombosis more effectively with reduced risks of bleeding. The main objective of this proposal is to develop these promising drug candidates for prevention of NH and improving the function and survival of AVGs. If successful, this strategy can be applied to AVFs. The specific aims of the phase II proposal are: Specific aim 1: Establish pilot-scale processes for production of ANV-6L15 and TAP-ANV. A bench process developed in phase I will be adapted for pilot-scale production of the recombinant proteins. Specific aim 2: Examine therapeutic efficacies of TAP-ANV and ANV-6L15 in porcine hemodialysis vascular access models. Both NH formation and lumen patency will be examined using a porcine arteriovenous polytetrafluoroethylene (PTFE) graft (AVG) model. Currently there are no effective therapies to improve hemodialysis arteriovenous access longevity. Through this study we may provide a novel and simple therapeutic intervention to improve longevity of hemodialysis PTFE AVGs and AVFs. Results from this study will also provide critical data for IND filing and further clinical development.PUBLIC HEALTH RELEVANCE: Performance of hemodialysis procedure requires a functional vascular access which often fails within one year. This project will examine the therapeutic efficacy of two novel antithrombotic drug candidates in preventing hemodialysis arteriovenous graft failure.

Principal Investigator:

Tze-chein Wun
636-527-4545
tcwun@hotmail.com

Business Contact:

Txe C. Wun
636-527-4545
tcwun@hotmail.com
Small Business Information at Submission:

EVAS THERAPEUTICS, LLC.
613 HUNTLEY HEIGHTS DRIVE BALLWIN, MO -

EIN/Tax ID: 120001789
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No